Seroatlas · Human Serome Atlas

AGER

Advanced glycosylation end product-specific receptor

Also known as: RAGE, RAGE_HUMAN, SCARJ1, sRAGE

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q15109
Gene
AGER
Ensembl
ENSG00000204305
Chromosome
6
Canonical length
404 aa
Protein class
Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters
Subcellular location
Nucleoli fibrillar center,Plasma membrane,Cell Junctions
Secretome location
Secreted in other tissues
Quaternary structure
Homodimer

OverviewNCBI Gene

The advanced glycosylation end product (AGE) receptor encoded by this gene is a member of the immunoglobulin superfamily of cell surface receptors. It is a multiligand receptor, and besides AGE, interacts with other molecules implicated in homeostasis, development, and inflammation, and certain diseases, such as diabetes and Alzheimer's disease. Many alternatively spliced transcript variants encoding different isoforms, as well as non-protein-coding variants, have been described for this gene (PMID:18089847). [provided by RefSeq, May 2011]

Canonical amino-acid sequenceUniProt

404 residues, UniProt reviewed canonical sequence.

>Q15109|AGER
     1  MAAGTAVGAW VLVLSLWGAV VGAQNITARI GEPLVLKCKG APKKPPQRLE WKLNTGRTEA
    61  WKVLSPQGGG PWDSVARVLP NGSLFLPAVG IQDEGIFRCQ AMNRNGKETK SNYRVRVYQI
   121  PGKPEIVDSA SELTAGVPNK VGTCVSEGSY PAGTLSWHLD GKPLVPNEKG VSVKEQTRRH
   181  PETGLFTLQS ELMVTPARGG DPRPTFSCSF SPGLPRHRAL RTAPIQPRVW EPVPLEEVQL
   241  VVEPEGGAVA PGGTVTLTCE VPAQPSPQIH WMKDGVPLPL PPSPVLILPE IGPQDQGTYS
   301  CVATHSSHGP QESRAVSISI IEPGEEGPTA GSVGGSGLGT LALALGILGG LGTAALLIGV
   361  ILWQRRQRRG EERKAPENQE EEEERAELNQ SEEPEAGESS TGGP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AGER can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.41
Highest tissue expression
687 nTPM

Expression across tissuesHPA

Tissue

  • lung: 687 nTPM
  • thyroid gland: 40 nTPM
  • spleen: 6.5 nTPM
  • cerebellum: 5.8 nTPM
  • kidney: 5.4 nTPM
  • pituitary gland: 4.8 nTPM

Single-cell type

  • alveolar cells type 1: 1,357 nCPM
  • transitional alveolar cells: 68 nCPM
  • alveolar cells type 2: 34 nCPM
  • sertoli cells: 9.2 nCPM
  • microglia: 8.9 nCPM
  • astrocytes: 7.2 nCPM

Immune cell

  • classical monocyte: 0.1 nTPM
  • neutrophil: 0.1 nTPM
  • basophil: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM

Brain region

  • cerebral cortex: 0.9 nTPM
  • white matter: 0.7 nTPM
  • medulla oblongata: 0.5 nTPM
  • thalamus: 0.5 nTPM
  • cerebellum: 0.4 nTPM
  • choroid plexus: 0.4 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.35
gnomAD pLI
0
gnomAD missense Z
0.09
DepMap mean gene effect
0.07
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of AGER in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AGER as an antibody target. Whether an autoantibody or antibody against AGER could matter depends on whether native AGER is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AGER is annotated at the cell surface, where native AGER is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label AGER as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/AGER. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...